News & Updates

Stereotactic body radiotherapy (SBRT) provides comparable 5-year biochemical progression-free survival (PFS) and is associated with slightly lower rates of gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional radiotherapy (RT) in Chinese patients with low- to intermediate-risk prostate cancer, according to a real-world study in Hong Kong.

Encorafenib plus binimetinib’s efficacy, safety and pharmacokinetics are consistent between Chinese patients and the global population, according to the results of the ongoing OCEAN II phase II trial in metastatic non-small-cell lung cancer (NSCLC) with BRAF^V600E mutation.

Combining neratinib with trastuzumab is associated with longer duration of response and progression-free survival (PFS) vs neratinib alone in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC), according to the results of the open-label phase II SUMMIT trial.

Better access to dermatologic care enables earlier melanoma detection at the population level, suggests a US study, noting an association between greater dermatologist density and a lower proportion of melanoma cases diagnosed at a late stage.

Radiation cystitis (RC) and radiation proctitis (RP) are common complications of radiotherapy (RT) in patients with prostate cancer, each with a 10-year cumulative incidence of ≥20 percent, according to researchers from the Chinese University of Hong Kong.